<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02934139</url>
  </required_header>
  <id_info>
    <org_study_id>N91115-1HS-08</org_study_id>
    <nct_id>NCT02934139</nct_id>
  </id_info>
  <brief_title>MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9)</brief_title>
  <acronym>(SNO-9)</acronym>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of N91115 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nivalis Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nivalis Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is designed to assess the safety and tolerability of escalating, multiple
      ascending doses of Cavosonstat (N91115) in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess the safety and tolerability of escalating, multiple ascending doses of
      Cavosonstat (N91115) in healthy subjects.

      Approximately 5 ascending cohorts are planned with approximately 8 subjects per cohort (6
      active, 2 placebo). Each subject will undergo screening (Day -28 to Day -2) and, if eligible,
      return to the unit on Day -1 when eligibility will be reconfirmed.

      Eligible subjects will be randomized in a 3:1 ratio to receive investigational medicinal
      product (IMP) N91115 (daily [QD] or every 12 hours [Q12H]) or matching placebo (QD or Q12H)
      for 7 days and will be followed for safety while housed in the clinical research unit (CRU)
      until discharge on Day 8. Pharmacokinetics will be followed from Study Day 1 through the
      morning of Study Day 8. The subjects will be discharged from the CRU and complete the post
      treatment withdrawal phase, including a follow-up phone call on Day 15.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>14 days</time_frame>
    <description>Safety assessments based on clinical evaluations, laboratory assessments, and adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of N91115 and metabolites (Amount of analyte excreted in the urine [Ae])</measure>
    <time_frame>7 days</time_frame>
    <description>Pharmacokinetic parameter of N91115 and metabolites will be measured in urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of N91115 and metabolites (% analyte excreted in the urine [Fe])</measure>
    <time_frame>7 days</time_frame>
    <description>Pharmacokinetic parameter of N91115 and metabolites will be measured in urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of N91115 and metabolites (area under the curve [AUC])</measure>
    <time_frame>7 days</time_frame>
    <description>Pharmacokinetic parameter of N91115 and metabolites will be measured in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of N91115 and metabolites (maximum concentration [Cmax])</measure>
    <time_frame>7 days</time_frame>
    <description>Pharmacokinetic parameter of N91115 and metabolites will be measured in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of N91115 and metabolites (clearance [CL])</measure>
    <time_frame>7 days</time_frame>
    <description>Pharmacokinetic parameter of N91115 and metabolites will be measured in urine and plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of N91115 and metabolites (accumulation index [Racc])</measure>
    <time_frame>7 days</time_frame>
    <description>Pharmacokinetic parameter of N91115 and metabolites will be measured in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of N91115 and metabolites (Terminal elimination half-life [t1/2])</measure>
    <time_frame>7 days</time_frame>
    <description>Pharmacokinetic parameter of N91115 and metabolites will be measured in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of N91115 and metabolites (time of maximum concentration [Tmax])</measure>
    <time_frame>7 days</time_frame>
    <description>Pharmacokinetic parameter of N91115 and metabolites will be measured in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of N91115 and metabolites (metabolite to parent exposure ratio [M/P ratio])</measure>
    <time_frame>7 days</time_frame>
    <description>Pharmacokinetic parameter of N91115 and metabolites will be measured in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of N91115 and metabolites (terminal elimination rate constant [lambda z])</measure>
    <time_frame>7 days</time_frame>
    <description>Pharmacokinetic parameter of N91115 and metabolites will be measured in plasma.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Cavosonstat (N91115) 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Every 12 hour oral dosing of N91115 for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cavosonstat (N91115) 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Every 12 hour oral dosing of N91115 for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cavosonstat (N91115) 1200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily oral dosing of N91115 for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cavosonstat (N91115) 800 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Every 12 hour oral dosing of N91115 for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo. Oral dosing every 12 hour or once daily for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cavosonstat</intervention_name>
    <description>CFTR modulator that stabilizes CFTR</description>
    <arm_group_label>Cavosonstat (N91115) 400 mg</arm_group_label>
    <arm_group_label>Cavosonstat (N91115) 600 mg</arm_group_label>
    <arm_group_label>Cavosonstat (N91115) 1200 mg</arm_group_label>
    <arm_group_label>Cavosonstat (N91115) 800 mg</arm_group_label>
    <other_name>N91115</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent

          2. Healthy, determined at the screening medical evaluation (including but not limited to
             medical history, physical examination, and clinical laboratory evaluations)

          3. Male or female, between 18 and 55 years of age, inclusive at screening

          4. Caucasian (as reported by patient)

          5. The following applies to female subjects:

               1. Negative serum pregnancy test (for women of child-bearing potential) at screening
                  and negative urine pregnancy at Day -1

               2. Willing to use at least 1 highly effective method of birth control (excluding
                  hormonal contraceptives) after signing consent, including abstinence which must
                  be in use from the time of consent through the 30 days after completing the
                  double-blind study drug

          6. The following applies to male subjects:

               1. Agrees to use a condom or abstinence, and agrees to refrain from sperm donation
                  from date of informed consent signing through the 30 days after completing the
                  double-blind study drug or

               2. Has documentation of azoospermia or vasectomy

          7. Non-smoker (or other nicotine user) as determined by history (no nicotine use over the
             past 6 months) and a negative cotinine test at screening and Day -1

          8. Body mass index between 18 and 32 kg/m2 inclusive at screening, and weighs at least 50
             kg at screening

          9. No clinically significant vital sign findings including no clinically significant
             abnormal findings related to their systolic or diastolic BP at screening or prior to
             dosing on Day 1, per the investigator's judgment.

         10. No clinically significant abnormal findings in 12-lead ECG, per the investigator's
             judgment, at screening or prior to dosing on Day 1

         11. No clinically significant abnormalities in hematology, clinical chemistry, and
             urinalysis results that would interfere with the study assessments at screening

        Exclusion Criteria:

          1. History of any illness or condition that in the opinion of the investigator could
             confound the results of the study or pose additional risk when administered IMP, such
             as clinically significant history or evidence of cardiovascular, respiratory, hepatic,
             renal, gastrointestinal, endocrine, neurological, immunological, or psychiatric
             disorder(s) as determined by the investigator or designee

          2. Concurrent disease or condition, that, in the opinion of the investigator, would make
             the subject unsuitable for participation in the clinical study

          3. Any of the following findings on a 12-lead ECG done at screening:

               1. HR &lt; 45 bpm or &gt; 95 bpm

               2. QTcF &gt; 450 msec for males and &gt;470 msec for females

               3. PR &gt; 220 msec

               4. QRS duration &gt; 110 msec

               5. ST segment abnormal

               6. T-wave changes

               7. QRS, ST, or T-wave findings making it technically difficult to determine the QT
                  intervals

          4. Any of the following on 24-hour ambulatory ECG (Holter) monitoring at screening:

             a. Supraventricular ectopy i. Singlets: &gt; 200 / 24 hours ii. Couplets: &gt; 20 / hour
             iii. Runs: &gt; 10 beats b. Ventricular ectopy i. Unifocal singlets: &gt; 100 / 24 hours ii.
             Unifocal couplets: &gt; 20 / hour iii. Complex of multifocal singlets: &gt; 50 / 24 hours
             iv. Complex of multifocal couplets: &gt; 10 / 24 hours v. Any Run (ventricular
             tachycardia) c. Heart rate i. &lt; 40 bpm for 1 minute while awake ii. &lt; 35 bpm for 3
             minutes while asleep iii. &gt; 120 bpm for 3 minutes (when not exercising) iv. Pauses &gt;
             2000 msec d. 2nd or 3rd degree AV block e. Intraventricular conduction delay (IVCD)
             with QRS duration &gt; 120 msec or right bundle branch block (RBBB) or left buddle branch
             block (LBBB) other than rare RBBB f. Atrial flutter or atrial fibrillation regardless
             of rate

          5. Disorder that would interfere with the absorption, distribution, metabolism, or
             excretion of drugs as determined by the investigator

          6. History of alcohol abuse or drug abuse (including cannabis, cocaine, and opioids) in
             the year prior to screening

          7. Positive alcohol test at screening or Day -1.

          8. Positive drug test (including but not limited to cocaine, amphetamines, barbiturates,
             opiates, benzodiazepines) at screening or Day -1.

             a. A positive drug test for cannabinoids at screening will be allowed if the subject
             agrees to abstain from use of all forms of cannabinoids during screening and
             throughout the study and has a negative test at Day -1

          9. Positive screening test for Hepatitis B surface antigen, Hepatitis C antibody, or
             human immunodeficiency virus (HIV) antibody.

         10. Unwilling to limit consumption of coffee and caffeine-containing foods and beverages
             from Day -1 until discharge on Day 8.

         11. Unwilling to avoid use of alcohol or alcohol-containing foods, medications, or
             beverages from Day -1 until discharge on Day 8.

         12. Subject has donated blood (&gt; 500 mL) or blood products within 56 days prior to Day -1.

         13. Use of vitamins from Day -7 until end-of-study follow up call, and use of
             over-thecounter (OTC) medications, prescription medications, or herbal remedies from
             Day - 14 until end-of-study follow-up call. By exception, acetaminophen â‰¤ 1000 mg/day
             is permitted except within 48 hours prior to Day -1. Hormone replacement therapy (HRT)
             and hormonal contraception is allowed throughout the study. The Medical Monitor and
             Principal Investigator may allow certain OTC medications by exception if they are not
             likely to affect study conduct and output.

         14. Use of an investigational drug within 30 days prior to Day 1 dosing.

         15. Unwilling to abstain from vigorous exercise from Day -1 until discharge on Day 8.

         16. Problems understanding the protocol requirements, instructions and study related
             restrictions, the nature, scope, and possible consequences of the clinical study.

         17. Unlikely to comply with the protocol requirements, instructions, and study related
             restrictions; e.g., uncooperative attitude, unavailable for follow-up call, and/or
             improbability of completing the clinical study.

         18. History of bleeding disorders (i.e., severe hemorrhage, melena, rectal bleeding,
             nosebleeds, bruising, etc.).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Williams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Davita Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2016</study_first_submitted>
  <study_first_submitted_qc>October 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2016</study_first_posted>
  <last_update_submitted>January 27, 2017</last_update_submitted>
  <last_update_submitted_qc>January 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>N91115</keyword>
  <keyword>Cavosonstat</keyword>
  <keyword>Healthy Volunteer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

